<DOC>
	<DOCNO>NCT01214577</DOCNO>
	<brief_summary>This study primarily design evaluate safety tolerability PEP005 Gel , 0.015 % administer three consecutive day photo-damaged skin face . The secondary endpoint determine efficacy PEP005 Gel , 0.015 % administer three consecutive day patient photo-damaged skin face .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy PEP005 ( Ingenol Mebutate ) Gel , 0.015 % , Patients With Photo-damaged Skin</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Male female patient age 30 65 year . 2 . Female patient must either : Nonchildbearing potential , provide laboratory confirm serum follicle stimulate hormone ( FSH ) level â‰¥ 40mIU/ml confirm clinical history sterility ( e.g. , patient without uterus ) ; Childbearing potential , provide negative urine pregnancy test result prior study treatment , rule pregnancy . 3 . Patient provide informed consent document signing Informed Consent Form ( ICF ) prior studyrelated procedure , include alteration medication preparation study entry . 4 . Patient agree allow photograph select treatment area take used part study data package . Exclusion Criteria 1 . Known sensitivity allergy ingredient PEP005 ( ingenol mebutate ) Gel . 2 . Current enrolment participation clinical research study within 30 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>PEP005</keyword>
	<keyword>Peplin</keyword>
	<keyword>Photo-damage</keyword>
</DOC>